Commitments and Contingencies (Actions In Which We Are The Defendant) (Detail) £ in Millions, $ in Millions	1 Months Ended
	Oct. 31, 2017 USD ($)	Apr. 30, 2017	Mar. 31, 2015 Patents	Mar. 31, 2013 lagoon	Oct. 01, 2017 Claim	Dec. 31, 2016 GBP (£)
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]
Loss Contingencies [Line Items]
Number of patents			6
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Claims dismissed			4
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of patents			2
Xtandi [Member] | Regents Versus Medivation [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Percentage of payments Medivation received sought by Regents		10.00%
Damages from Product Defects [Member] | Class Action Versus American Optical Corporation And Various Other Defendants [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims | Claim					56,500
Average Wholesale Price [Member] | State of Illinois Versus Pfizer [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims | Claim					1
Environmental Remediation Litigation [Member]
Loss Contingencies [Line Items]
Number of lagoons | lagoon				2
Violation of Antitrust Laws [Member] | Phenytoin Sodium Capsules [Member]
Loss Contingencies [Line Items]
Imposed fine | £						£ 84.2
Subsequent Event [Member] | Celebrex [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Amount awarded to other party | $	$ 94